Cardiac Safety Assessment. In-Vitro/In-Vivo Extrapolation
|
|
- Marion McCoy
- 6 years ago
- Views:
Transcription
1 Cardiac Safety Assessment In-Vitro/In-Vivo Extrapolation
2 Drugs removed from the market for arrhythmia risk Courtesy of Dr. Norman Stockbridge Copyright 2014 Certara, L.P. All rights reserved. 2
3 Let s have a closer look at Cisapride Copyright 2014 Certara, L.P. All rights reserved. 3
4 Let s have a closer look at Cisapride Metoprolol Ondansetron Ranitidine Phenytoine Amiodarone Copyright 2014 Certara, L.P. All rights reserved. 4
5 Let s have a closer look at Cisapride Copyright 2014 Certara, L.P. All rights reserved. 5
6 And Now For Something Completely Different Trimebutine Copyright 2014 Certara, L.P. All rights reserved. 6
7 And Now For Something Completely Different Trimebutine Eudravigilance system query Copyright 2014 Certara, L.P. All rights reserved. 7
8 And Now For Something Completely Different Trimebutine Copyright 2014 Certara, L.P. All rights reserved. 8
9 Physiology disruption can it be clinically significant? Copyright 2014 Certara, L.P. All rights reserved. 9
10 Physiology disruption can it be clinically significant? Bisacodyl During her hospitalization she had two episodes of torsades de pointes requiring cardiac defibrillation. [ ] she admitted her laxative abuse and surrendered her supply of Dulcolax tablets. Pantoprazol 53-year-old chronic alcoholic male patient, [ ] on a proton pump inhibitor for peptic ulcer prophylaxis, which resulted in resistant hypomagnesemia associated with a storm of life-threatening arrhythmias, namely Torsades de Pointes (TdP) Copyright 2014 Certara, L.P. All rights reserved. 10
11 TdP risk surrogates one drug really? IKr IC 50 = 5.95 µm INa IC 50 = 38 µm IKr IC 50 = 12.1 µm INa IC 50 = 8.5 µm Redfern system Category 5 (no TdP) Mirams system Category 5 (no TdP) pro-drug high extraction rate, low concentration Kramer system Category 0 (no TdP) CredibleMeds possible TdP risk Figure from Dimmit DC et al. CancChemPharm, 1999; 43: Copyright 2014 Certara, L.P. All rights reserved. 11
12 One drug really? Problem insight parent+metabolites PO IV single drug analysis might be misleading multiple drug analysis might be necessary metabolite(s) should be analyzed in parallel with the parent compound pharmacokinetics plays significant role Copyright 2014 Certara, L.P. All rights reserved. 12
13 One drug really? Problem insight metabolites Copyright 2014 Certara, L.P. All rights reserved. 13
14 TdP risk of the drug combinations Droperidol and ondansetron both found to prolong the QT interval Utilized in the treatment of postoperative nausea and vomiting May be used in combination The effects of droperidol and ondansetron in combination on QT interval duration unknown Copyright 2014 Certara, L.P. All rights reserved. 14
15 TdP risk one drug really? Copyright 2014 Certara, L.P. All rights reserved. 15
16 TdP risk one drug really? Copyright 2014 Certara, L.P. All rights reserved. 16
17 TdP risk one drug really? Copyright 2014 Certara, L.P. All rights reserved. 17
18 One drug really? Problem insight PD DDIs single drug analysis does not explain the clinical effect multiple drug analysis might be necessary perpetrator(s) should be analyzed in parallel with the parent compound pharmacokinetics not significant how does it transfer to TdP risk? Copyright 2014 Certara, L.P. All rights reserved. 18
19 Exposure where and how? Copyright 2014 Certara, L.P. All rights reserved. 19
20 TdP risk surrogates problems example Risperidone Copyright 2014 Certara, L.P. All rights reserved. 20
21 TdP risk surrogates problems example Risperidone Classification Redfern class 5 (safe) Mirams class 5 (safe) Clinical cases 15 LQTc cases recently reviewed 6 out of 15 (+)TdP Kramer (+)TdP CredibleMeds possible TdP risk Rajabi et al. (2011) sudden cardiac death -> risk factors were female sex, cotrimoxazole, and risperidone Raviña et al. (2007) TdP -> risk factors were female sex, age, and risperidone Blaschke et al. (2007) TdP -> risk factors were female sex, age, bradycardia, and concomitant use of risperidone, citalopram, and co-trimoxazole Novalbos et al. (2010) QT prolongation -> CYP2D6 Genotype (metabolites role) Llerena et al. (2004) QT prolongation -> CYP2D6 Genotype (metabolites role) Copyright 2014 Certara, L.P. All rights reserved. Viewerg 2013 Psychopharmacology 228:
22 Sola dosis facit venenum was Paracelsus right? Eudravigilance system query Copyright 2014 Certara, L.P. All rights reserved. 22
23 Algorithms for the TdP risk prediction issues CHANNELS INHIBITION SOURCE and QUALITY of INPUT DATA RISK CLASSIFICATIONS PREDICTION ALGORITHMS and ENDPOINTS EXPOSURE (active concentration surrogates) ACTIVE METABOLITES and INTERACTING DRUGS DEMOGRAPHIC, (PATHO)PHYSIOLOGICAL and GENETIC VARIABILITY COMORBIDITY DRUGS TRIGGERED PHYSIOLOGY MODIFICATION DIETARY HABITS NON-ELECTROPHYSIOLOGICALLY TRIGGERED QT prol / TdP PRODRUGS Copyright 2014 Certara, L.P. All rights reserved. 23
24 Separating Systems & Drug Information IVIVE Systems Data Drugs Data Trial Design Age Weight Tissue Volumes Tissue Composition Cardiac Output Tissue Blood Flows Cardiac Myocytes Volume Electric capacitance Plasma ions MW LogP pka Protein binding BP ratio In vitro Metabolism Permeability, Transport Ionic currents inhibition Dose Route Frequency Co-administered drugs Populations studied Time of the day Mechanistic IVIVE PBPK/PBPD models Prediction of drug PK (PD) in population of interest Copyright 2014 Certara, L.P. All rights reserved. 24
25 Simcyp/Certara proposition Cardiac Safety Simulator PURPOSE OF THE CSS Integrate available in vitro data Utilize the early clinical data if accessible Account for the inter-individual variability (despite of what people say - TdP is NOT a yes/no event) Analyze the simulated data Assess both QT and non-qt toxicities Copyright 2014 Certara, L.P. All rights reserved. 25
26 Multiple endpoints from one system Cardiac Safety Simulator exposure SIMCYP multiple drugs cell contractility - EM window herg in silico (QSAR) other ion currents other in ion other silico ion currents (QSAR) in silico currents other in silico ion currents (QSAR) (QSAR) in silico (QSAR) herg in vitro (measured) other ion currents other in ion other vitro ion currents (measured) in vitro currents other in ion vitro (measured) currents (measured) in vitro (measured) CONTRACTILITY MODEL HUMAN HEART LEFT VENTRICULAR CELL MODEL virtual population demography action potential (APD90) - AP prolongation - AP shape analysis - EADs pseudoecg (QTc) physiology genetics Copyright 2014 Certara, L.P. All rights reserved. - QT prolongation - iceb - J-T peak, T peak -T end 26
27 Simulation results Mean ΔQTc (SD) [ms] Risperidone observed predicted SOURCE and QUALITY of INPUT DATA RISK CLASSIFICATIONS PREDICTION ALGORITHMS and ENDPOINTS EXPOSURE (active concentration surrogates)! ACTIVE METABOLITES and INTERACTING DRUGS 5 0 RISPERIDONE DEMOGRAPHIC, (PATHO)PHYSIOLOGICAL and GENETIC VARIABILITY DRUGS TRIGGERED PHYSIOLOGY MODIFICATION Harrigan 2004 JClinPsychopharm 24:62 69 Glinka 2014 CompBiolMed 47:20 26 Copyright 2014 Certara, L.P. All rights reserved. 27
28 Simulation results Mean ΔQTc (95% CI) [ms] Risperidone plasma heart 5 2 EnhQSAR predicted IC50 [µm] IKr IKs INa ICaL risperidone_cid_ paliperdione_cid_ ΔQTc obs ΔQTc pred SOURCE and QUALITY of INPUT DATA EXPOSURE (active concentration surrogate) ACTIVE METABOLITES GENETIC VARIABILITY 0 EM IM PM UM Copyright 2014 Certara, L.P. All rights reserved. Novalbos 2014 JClinPsychopharm 30:
29 Simulation results ACUTE INTOXICATION - IVIVE at the individual level - RESULTS Citalopram 36-yo woman after a suicidal attempt high dose of citalopram measured plasma concentration (~33 hour after the last dose) - Citalopram 477 ng/ml (1.47 μm); therapeutic concentration: ng/ml ( μm) - Desmethylocitalopram ng/ml (0.4 μm); therapeutic concentration: ng/ml ( μm) hypokalemia 3.1 mmol/l; heart rate /minute Copyright 2014 Certara, L.P. All rights reserved. 29
30 Simulation results ACUTE INTOXICATION - IVIVE at the individual level - RESULTS Citalopram (+ desmethylcitalopram) CSS Ionic current Citalopram [IC 50 ]/n Reference and/or model input parameters Desmethylcitalopram [IC 50 ]/n Reference and/or model input parameters I Kr 3.97/0.75 [Witchel 2002] 1.59/1 QSAR predicted I Ca 65/1 [Witchel 2002] 2.93/1 QSAR predicted 1 K + - physiological (4.1 mm ±CV 10%) RR physiological (750 ms ±CV 5%) heart drugs concentration (Kp~1.2) 2 K + - disrupted (3.1 ±CV 10%) RR disrupted (500 ms ±CV 5%) heart drugs concentration (Kp~1.2) 5 Copyright 2014 Certara, L.P. All rights reserved. 30
31 Simulation results AP (ms) ACUTE INTOXICATION - IVIVE at the individual level - RESULTS Citalopram (+ desmethylcitalopram) OBS PRED_2 PRED_1 Mean-APD90 (ms) (4.3) 394 (6.5) Triangulation - 54 (5.3) 42 (4.2) CSS Mean-QTcB (ms) (22.3) 436 (19.0) Time (ms) Copyright 2014 Certara, L.P. All rights reserved. 31
32 AP (ms) Simulation results ACUTE INTOXICATION - IVIVE at the individual level - RESULTS Citalopram (+ desmethylcitalopram) CSS Time (ms) Copyright 2014 Certara, L.P. All rights reserved. 32
33 Acknowledgements Simcyp Nikunjkumar Patel Amin Rostami-Hodjegan Jagiellonian University Medical College Barbara Wiśniowska Anna Glinka Kamil Fijorek Aleksander Mendyk Copyright 2014 Certara, L.P. All rights reserved. 33
34 Conclusions IVIVE in the TdP risk assessment area REMEDY not yet USEFUL TOOL yes, already is (borderline drugs) WHERE different scenarios testing POPULATION ANALYSIS important ENVIRONMENTAL PARAMETERS matters I HOPE YOU DON T AGREE AND WE CAN HAVE A NICE ARGUMENT Copyright 2014 Certara, L.P. All rights reserved. 34
35 THANK YOU
36 Simulation results ANTIARRHYTHMIC DRUG - IVIVE at the population level - RESULTS Flecainide Copyright 2014 Certara, L.P. All rights reserved. 36
37 Simulation results ANTIARRHYTHMIC DRUG - IVIVE at the population level - RESULTS Flecainide 24 healthy individuals (12M + 12F) two formulations (IR-solid, CR-open) two doses (100 mg-circle, 200 mg-sqaure) two scenarios (single, multiple dose) Copyright 2014 Certara, L.P. All rights reserved. 37
38 PRED Simulation results PRED PRED PRED ANTIARRHYTHMIC DRUG - IVIVE at the population level - RESULTS Flecainide I kr 3.91 µm (HEK, 37 0 C); I Na 0.9 µm (HEK, 22 0 C) analysed endpoint - ΔQRS CSS o 100 IR 100 CR 200 IR 200 CR OBS OBS OBS OBS Copyright 2014 Certara, L.P. All rights reserved. 38
Benchmarking In Silico Models and Candidate Metrics for Assessing the Risk of Torsade de Pointes
Benchmarking In Silico Models and Candidate Metrics for Assessing the Risk of Torsade de Pointes Sara Dutta Division of Applied Regulatory Science/OCP/CDER CRSC/HESI/SPS/FDA Meeting December 11, 2014 Silver
More informationSuccesses and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative
Successes and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative Gary Gintant Dept. Integrative Pharmacology Integrated Sciences and Technology AbbVie For the CiPA
More informationQT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency
QT prolongation and drug-drug interactions Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency Disposition Introduction to QT prolongation Three relevant DDI scenarios Concluding
More informationIn Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative
In Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative Gary Gintant, AbbVie for the Comprehensive in Vitro ProArrhythmia Assay Group Hot
More informationDrug induced QT prolongation and Torsades de Pointes (TdP) Mark Friesen, PharmD March 13, 2013
Drug induced QT prolongation and Torsades de Pointes (TdP) Mark Friesen, PharmD March 13, 2013 None Conflict of Interest TdP: Learning objectives To review the pathophysiology of QT prolongation and TdP
More informationAntiarrhythmic Drugs
Antiarrhythmic Drugs DR ATIF ALQUBBANY A S S I S T A N T P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y C O N S U L T A N T C A R D I O L O G Y & I N T E R V E N T I O N A L E P A C H D /
More informationTdP Mechanisms and CiPA
TdP Mechanisms and CiPA Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison Cardiac Safety Research Consortium Hilton Washington DC December 6, 2016 Disclosures
More informationThe QT Interval Safety Endpoint for DR- TB trials. Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology)
The QT Interval Safety Endpoint for DR- TB trials Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology) The ECG tracing Physiology of a cardiac myocyte Flow of ions (Na
More information12/19/16. Disclosures
@atriumrx Don t Miss a Beat! Practical Tips on Managing Drug-Induced QTc Prolongation Sandeep Devabhakthuni, PharmD, BCPS- AQ Cardiology Assistant Professor University of Maryland School of Pharmacy Disclosures
More informationDrugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification
Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,
More informationDrug-induced effects on the heart: insights from HPC simulations
Drug-induced effects on the heart: insights from HPC simulations Blanca Rodriguez Computational Biology Group University of Oxford July 1 st, 2009 Acknowledgements Esther Pueyo, Lucia Romero, Alberto Corrias,
More informationDeveloping and Validating an In Silico Model for Proarrhythmia Risk Assessment Under the CiPA Initiative
Developing and Validating an In Silico Model for Proarrhythmia Risk Assessment Under the CiPA Initiative May 2018 Zhihua Li, PhD for the CiPA In Silico Working Group US Food and Drug Administration This
More informationMechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS)
Mechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS) Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison CSRC-HESI-FDA Rechanneling the Current Cardiac
More informationTCP Transl Clin Pharmacol
TCP 2018;26(4):145-149 https://doi.org/10.12793/tcp.2018.26.4.145 Five years of the CiPA project (2013 2018) - what did we learn? Dong-Seok Yim* Department of Clinical Pharmacology and Therapeutics, Seoul
More informationUsing virtual populations to solve drug development problems. Iain Gardner Head of Translational DMPK Science SIMCYP
Using virtual populations to solve drug development problems Iain Gardner Head of Translational DMPK Science SIMCYP Prediction of human PK (PD) in virtual individuals In vitro system In vitro CLu int Scaling
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes. on the ACEA xcelligence RTCA CardioECR
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR Application Note Version 2.1 / March 2018 Contents 1. Introduction 1 2. Assessment of pro-arrhythmic
More informationMetrion Biosciences: the ion channel specialists
Metrion Biosciences: the ion channel specialists In depth profiling of human ipsc cardiomyocytes: From electrophysiology to phenotypic assays Saïd El-Haou, PhD 30 November 2017 www.metrionbiosciences.com
More informationCiPA, Pre-clinical Testing. Derek Leishman PhD DSP & ICH S7B
CiPA, Pre-clinical Testing Derek Leishman PhD DSP & ICH S7B Outline Introduction Scenarios Conclusion Expressing an opinion What is not covered? Analysis/critique of the components too little time to try
More informationComparison of different proarrhythmia biomarkers in isolated rabbit hearts
Comparison of different proarrhythmia biomarkers in isolated rabbit hearts Summary of PhD Thesis Szabolcs Orosz, MSc Supervisor: Attila Farkas MD, PhD 2nd Dept. of Internal Medicine and Cardiology Centre
More informationDrug-induced arrhythmogenesis. Prediction and Mechanisms. Blanca Rodriguez and Computational Biology Group University of Oxford
Drug-induced arrhythmogenesis. Prediction and Mechanisms Blanca Rodriguez and Computational Biology Group University of Oxford Feb 3 rd, 29 Work done by Esther Pueyo, Lucia Romero, Alberto Corrias, Martin
More informationPreparing for Changing Cardiac Safety Regulations. Joy Olbertz, PharmD, PhD
Preparing for Changing Cardiac Safety Regulations Joy Olbertz, PharmD, PhD Questions? Do I still have to assess proarrhythmic potential of my compound in a Thorough QT (TQT) study? If I have a TQT to conduct,
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationPreclinical Perspectives of QT Outlook from ICH Guidelines
Biometry in Early Clinical Research QT/QTc Interval Workshop in Heidelberg, November 17-19, 2005 Preclinical Perspectives of QT Outlook from ICH Guidelines Gerd Bode, M.D.,Ph.D. Frelance Consultant, e-mail
More informationModeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment
Citation: CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 175 188; VC 2015 ASCPT All rights reserved doi:10.1002/psp4.18 REVIEW Modeling and Simulation Approaches for Cardiovascular Function and Their Role
More informationBlocking the Late Sodium Current
Non-classical Targets in Antiarrhythmic Therapy Blocking the Late Sodium Current Luiz Belardinelli, MD SVP, Cardiovascular Therapeutics Gilead Sciences, CA, USA Madrid June 28, 2011 Disclosures: Full time
More informationVolume 9, Number 14 September 2015
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationMichigan EMS. Medication In-Service: Ondansetron (Zofran) ODT
Michigan EMS Medication In-Service: Ondansetron (Zofran) ODT Course Objectives Identify the location of ondansetron (Zofran) ODT in the SEM Drug Box, as well as how it may be packaged. Describe the pharmacokinetics
More informationQT Interval: The Proper Measurement Techniques.
In the name of God Shiraz E-Medical Journal Vol. 11, No. 2, April 2010 http://semj.sums.ac.ir/vol11/apr2010/88044.htm QT Interval: The Proper Measurement Techniques. Basamad Z*. * Assistant Professor,
More informationAntiarrhythmics & QT Prolongation: Avoiding Drug Interactions
Antiarrhythmics & QT Prolongation: Avoiding Drug Interactions M E L I N D A D E U B N E R, P H A R M D, B C C C P A w e b i n a r f o r H e a l t h T r u s t m e m b e r s A u g u s t 2 4, 2 0 1 8 Disclosures
More informationTargeting the late sodium channel: A new antiarrhythmic paradigm?
Targeting the late sodium channel: A new antiarrhythmic paradigm? Wojciech Zareba, MD, PhD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Disclosures: - Gilead Sciences:
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationNcardia. Assessment of pro-arrhythmic effects in Pluricyte Cardiomyocytes. using the Axion BioSystems Maestro TM MEA system
Ncardia Stem cell experts Assessment of pro-arrhythmic effects in Pluricyte Cardiomyocytes using the Axion BioSystems Maestro TM MEA system Application note Version 2.0 Contents 1. Introduction 1 2. Assessment
More informationCardiac arrest after ibogaine intoxication
1 of 6 10/28/2018 8:18 PM J Arrhythm. 2018 Aug; 34(4): 455 457. Published online 2018 Jun 12. doi: [10.1002/joa3.12061] PMCID: PMC6111465 PMID: 30167018 Cardiac arrest after ibogaine intoxication Christian
More informationIs There a Genomic Basis to Acquired Channelopathic disease
Is There a Genomic Basis to Acquired Channelopathic disease Yaniv Bar-Cohen, M.D. Associate Professor of Pediatrics Division of Cardiology / Electrophysiology Children s Hospital Los Angeles Keck School
More informationDrug-induced cardiotoxicity: screening methods, regulatory context, commercial environment. Beremans Ltd / Insight Pharma Reports April 2008
Drug-induced cardiotoxicity: screening methods, regulatory context, commercial environment. Overview Beremans Ltd / Insight Pharma Reports April 2008 This report identifies and discusses methods, products
More informationICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS.
European Medicines Agency London, 25 May 2005 CHMP/ICH/2/04 ICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS ICH Step 4 NOTE FOR
More informationInterpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety?
Interpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety? Hao Zhu, Ph.D. Scientific Lead, QT-IRT, FDA (Dec 10, 2010) Disclaimer: The views expressed in this talk are those of
More information2/1/2013. Poisoning pitfalls. The original pitfall
The original pitfall Poisoning pitfalls Craig Smollin MD Associate Medical Director, California Poison Control System - SF Division Assistant Professor of Emergency Medicine, UCSF What will we talk about?
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19939 holds various files of this Leiden University dissertation. Author: Chain, Anne S.Y. Title: Mind the gap : predicting cardiovascular risk during drug
More informationEMEA PUBLIC STATEMENT ON THE RECOMMENDATION TO SUSPEND THE MARKETING AUTHORISATION FOR ORLAAM (LEVACETYLMETHADOL) IN THE EUROPEAN UNION
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 19 April 2001 EMEA/8776/01 EMEA PUBLIC STATEMENT ON THE RECOMMENDATION TO SUSPEND THE MARKETING
More informationSupplemental Information
Supplemental Information Article Title:The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Co-Administration with
More informationDesign and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience
Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience Dr. Manfred Wargenau, Institute, Düsseldorf OVERVIEW Clinical background The ICH E14 guideline / review
More informationRhythm and Blues Drugs and QT Prolongation
Rhythm and Blues Drugs and QT Prolongation Dr Martin Quinn St Vincents University Hospital Irish Medication Safety Network conference Farmleigh 18 Oct 2013 Drugs and QT Prolongation Anti-psychotic, antidepressant,
More informationMuhammad Fawad Rasool Feras Khalil Stephanie Läer
Clin Pharmacokinet (2015) 54:943 962 DOI 10.1007/s40262-015-0253-7 ORIGINAL RESEARCH ARTICLE A Physiologically Based Pharmacokinetic Drug Disease Model to Predict Carvedilol Exposure in Adult and Paediatric
More informationPHARMACOLOGY OF ARRHYTHMIAS
PHARMACOLOGY OF ARRHYTHMIAS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 27, 2012 Materials on: Exam #5 Required reading: Katzung, Chapter 14 1 CARDIAC ARRHYTHMIAS Abnormalities
More informationFor Discussion Purposes Only
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 Step 1 Draft 2 (July 17, 2003) Draft 3 (November 12, 2003), Draft 4 (June 10, 2004)
More informationGuidance for Industry
Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs U.S. Department of Health and Human Services Food and Drug Administration
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR Version 1.2 CONTENTS Getting started... 3 Technical support and training... 3 1. Introduction...
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationCan the Thorough QT Study Be Replaced? Norman Stockbridge Division of Cardiovascular and Renal Products FDA/CDER
Can the Thorough QT Study Be Replaced? Norman Stockbridge Division of Cardiovascular and Renal Products FDA/CDER Can the TQT study be replaced? Yes. Thank you. Any questions? Four genre of replacement
More information2009 Unit-Based Competencies
2009 Unit-Based Competencies Alameda County Medical Center Highland Hospital Emergency Department Janis Farnholtz Provinse, RN, MS, CNS, CEN, ED Clinical Nurse Specialist Nurses play a pivotal role in
More informationThe mechanism of the cardiac arrhythmias Norbert Jost, PhD
The mechanism of the cardiac arrhythmias Norbert Jost, PhD Department of Pharmacology & Pharmacotherapy, University of Szeged Division for Cardiovascular Pharmacology, Hungarian Academy of Sciences Szeged,
More informationDrug-induced QTc-prolongation: risk management in a community pharmacy
Drug-induced QTc-prolongation: risk management in a community pharmacy Eline Vandael Veerle Foulon Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium Email: Eline.Vandae@kuleuven.be;
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationIndustry Experience of the Concentration-QTc Relationship in Phase 1 Studies. Corina Dota, AstraZeneca
Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies Corina Dota, AstraZeneca CSRC-2 th February 2012 ICH E14 2.2.5 Alternative Strategies to Assess QT/QTc Interval Effects Alternatives
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department
More informationAnti-HERG activity and the risk of drug-induced arrhythmias and sudden death
European Heart Journal (2005) 26, 590 597 doi:10.1093/eurheartj/ehi092 Clinical research Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death M.L. De Bruin 1,2 *, M. Pettersson
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationJapanese Stem Cell Efforts
Japanese Stem Cell Efforts Yuko Sekino, Ph. D. Organizer of JiCSA Head, Division of Pharmacology, National Institute of Health Sciences (NIHS) Pharmaceutical and Medical Safety Bureau NI HS Since 1874
More informationxcelligence System RTCA Cardio Instrument
xcelligence System Application Note No. 15 January 2013 xcelligence System RTCA Cardio Instrument Preclinical Cardiac Safety Assessment using Human ipsc Derived icell TM Cardiomyocytes Introduction Over
More informationPrescriber Training Slide Deck
Prescriber Training Slide Deck 1 Contents Introduction CAPRELSA (vandetinib) Tablets Indication Risk of QT Prolongation, Torsades de pointes, and Sudden Death Patient Selection ECG and Electrolyte Monitoring
More informationthat number is extremely high. It s 16 episodes, or in other words, it s 14, one-four, ICD shocks per patient per day.
Doctor Karlsner, Doctor Schumosky, ladies and gentlemen. It s my real pleasure to participate in this session on controversial issues in the management of ventricular tachycardia and I m sure that will
More informationSEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !
Sudden cardiac death in the adult Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel.! " # $ % Cancers National Vital Statistics Report, Vol 49 (11), Oct. 12, 2001. 20% 25% State-specific
More informationB. 14 Antidysrhythmic drugs. a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification
B. 14 Antidysrhythmic drugs a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification I II III IV membrane stabilizers all ERP, ERP/APD, all except c APD classified
More informationDoes Low-dose Droperidol Increase the Risk of Polymorphic Ventricular Tachycardia or Death in the Surgical Patient?
Does Low-dose Increase the Risk of Polymorphic Ventricular Tachycardia or Death in the Surgical Patient? Gregory A. Nuttall, M.D.,* Ann M. Malone, B.S.N., Carrie A. Michels, B.S.N., Laurie C. Trudell,
More informationDrugs, herg and sudden death
Cell Calcium 35 () 53 57 Drugs, herg and sudden death A.M. Brown a,b, a MetroHealth Campus, Case Western Reserve University, Cleveland, OH 8, USA b ChanTest, Inc., 656 Neo Parkway, Cleveland, OH 8, USA
More informationProlonged QT Syndromes: Congenital and Acquired
Prolonged QT Syndromes: Congenital and Acquired April 30, 2014 Elizabeth S. Kaufman, MD I have no financial disclosures. MetroHealth Campus, Case Western Reserve University Prolonged QT Syndromes Congenital
More informationEvolution of strategies to improve preclinical cardiac safety testing
OPINION Evolution of strategies to improve preclinical cardiac safety testing Gary Gintant, Philip T. Sager and Norman Stockbridge Abstract The early and efficient assessment of cardiac safety liabilities
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationElectrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes
Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes Based on Data from the Telemetric and Holter ECG Warehouse (THEW) Initiative Jean-PhiIippe Couderc, PhD Center for Quantitative
More informationDevelopment of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization
Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization Nico Holmstock Scientist, Janssen R&D M CERSI 2017, BALTIMORE (USA) Canagliflozin An
More informationThe QT interval as it relates to the safety of non-cardiac drugs
European Heart Journal Supplements (2007) 9 (Supplement G), G3 G8 doi:10.1093/eurheartj/sum047 The QT interval as it relates to the safety of non-cardiac drugs Peter R. Kowey 1 * and Marek Malik 2,3 1
More informationSudden Cardiac Death Prevention: ICD Indications
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/sudden-cardiac-death-prevention-icdindications/3681/
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationAtrial Fibrillation 10/2/2018. Depolarization & ECG. Atrial Fibrillation. Hemodynamic Consequences
Depolarization & ECG Atrial Fibrillation How to make ORDER out of CHAOS Julia Shih, VMD, DACVIM (Cardiology) October 27, 2018 Depolarization & ECG Depolarization & ECG Atrial Fibrillation Hemodynamic Consequences
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationAdvances in Safety Pharmacology: Utilizing ipsc-derived cardiomyocytes in early stage safety pharmacology investigations. Blake Anson, PhD.
Advances in Safety Pharmacology: Utilizing ipsc-derived cardiomyocytes in early stage safety pharmacology investigations Blake Anson, PhD. Presentation Outline I. Safety Pharmacology and in-vitro models
More informationStudy Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;
The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAcquired QT prolongation and Torsades de Pointes: a review and case report
Acquired QT prolongation and Torsades de Pointes: a review and case report Alastair Gray, Conor McQuillan Royal Victoria Hospital Belfast Introduction As early as the 1920 s it was noted that several drugs
More informationMEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities
MEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities Event Presenter Date EMA Workshop 2017 Tessa de Korte, MSc 2017, October 5 Page 1 Ncardia at a glance Foundation Ncardia
More informationCAPRELSA (vandetanib) Tablets and Risk of QT Prolongation, Torsades de Pointes and Sudden Death
CAPRELSA (vandetanib) Tablets and Risk of QT Prolongation, Torsades de Pointes and Sudden Death Prescriber Training Pamphlet Introduction This training pamphlet has been developed as part of a REMS program
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationANTI - ARRHYTHMIC DRUGS
ANTI - ARRHYTHMIC DRUGS CARDIAC ACTION POTENTIAL K Out Balance Ca in/k out Na in K Out GENERATION OF ARRHYTHMIAS Four mechanisms of arrhythmia generation; Increased normal automaticity Abnormal automaticity
More informationChapter 16: Arrhythmias and Conduction Disturbances
Complete the following. Chapter 16: Arrhythmias and Conduction Disturbances 1. Cardiac arrhythmias result from abnormal impulse, abnormal impulse, or both mechanisms together. 2. is the ability of certain
More informationEXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS
EXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS Christine Garnett, PharmD DCRP, FDA April 6, 2016 CSRC/FDA Workshop: The Proarrhythmic Assessment of New Chemical Entities Disclosures
More informationAntiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017
Antiarrhythmic Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017 Types of Cardiac Arrhythmias Abnormalities of Impulse Formation: Rate disturbances. Triggered
More informationAntiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiarrhythmic Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 2 Ion Permeability Changes Potential Changes Genes and Proteins 3 Cardiac Na+ channels 5 6
More informationATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular
1 ATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationCONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT.
CONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT. SAHA Annual Congress 2017. Samkelo Jiyana, Adele Greyling, Andile Nxele, ZM,Makrexeni,L.Pepeta. BACKGROUND
More informationEMA EFPIA workshop Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development
EMA EFPIA workshop Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development Oscar Della Pasqua GSK Background Drugs that prolong QT
More informationHow do arrhythmias occur?
How do arrhythmias occur? An arrhythmia is an abnormal heart rhythm (= dysrhythmia). Can be fast (tachy) or slow (brady). Brady arrhythmias are usually due to conduc;on block, while tachyarrhythmias are
More informationAge and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study
Fijorek et al. Theoretical Biology and Medical Modelling 2013, 10:7 RESEARCH Open Access Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationMr. Eknath Kole M.S. Pharm (NIPER Mohali)
M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization
More informationManagement of Arrhythmia Syndromes in the Newborn and Very Young Child: Unique Risks & Barriers in this Age Population
Management of Arrhythmia Syndromes in the Newborn and Very Young Child: Unique Risks & Barriers in this Age Population Mitchell Cohen, MD FACC FHRS Co-Director Heart Center Chief of Pediatric Cardiology
More informationShort QT Syndrome: Pharmacological Treatment
Journal of the American College of Cardiology Vol. 43, No. 8, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.02.034
More informationICD Endpoints. Peter R. Kowey, MD, FACC, FAHA, FHRS Lankenau Medical Research Institute JeffersonMedical College Philadelphia, PA
ICD Endpoints Peter R. Kowey, MD, FACC, FAHA, FHRS Lankenau Medical Research Institute JeffersonMedical College Philadelphia, PA Disclosures Dr. Kowey has provided consultation to a number of device and
More informationActive Ondansetron. Virtual SPC for PSUR Synchronisation Scheme
Active Ondansetron Virtual SPC for PSUR Synchronisation Scheme This Virtual SPC is based on GlaxoSmithKline s Company Core Data Sheet (CCDS) for ondansetron. GSK does not believe that there are deficiencies
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More information